Английская Википедия:Bupropion/zonisamide
Шаблон:Short description Шаблон:Drugbox
Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[1][4][5]
See also
References
Шаблон:Ion channel modulators Шаблон:Monoamine reuptake inhibitors Шаблон:Nicotinic acetylcholine receptor modulators
Шаблон:Nervous-system-drug-stub
- Английская Википедия
- Abandoned drugs
- Anorectics
- Anti-obesity drugs
- Calcium channel blockers
- Carbonic anhydrase inhibitors
- Combination anti-obesity drugs
- Norepinephrine releasing agents
- Norepinephrine reuptake inhibitors
- Nicotinic antagonists
- Sodium channel blockers
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии